Ebenezer GJ, Polydefkis M, Scollard DM. 18 September 2016, posting date. Mechanisms of nerve injury in leprosy. In Scollard DM, Gillis TP (ed), International textbook of leprosy.

No funding has been declared.
Competing Interests: 
No competing interests have been stated.


Localization of M. leprae

Leprosy neuropathy is a slowly progressive sensorimotor polyneuropathy that can be either asymmetrical or symmetrical [1]. Mycobacterium leprae (M. leprae) is the only bacterium that infects the peripheral nervous system (PNS), specifically targeting the Schwann cells (SC) of myelinated and unmyelinated axons. M. leprae within a nerve fiber (see Chapter 2.4) is pathognomonic of leprosy (Figure 1A). Large clusters of M. leprae reside in SC and macrophages, which provide a safe haven for multiplication. Bacilli are also present in smaller numbers within perineurial cells, smooth muscles, hepatocytes, and endothelial cells of blood vessels in florid lepromatous leprosy, where they do not cause toxic injury to the residing cells [2], [3], [4]. M. leprae prefer the cooler areas of the body where they multiply, and inflammatory cells associated with the organism are observed predominantly in segments of nerve trunks that are in close proximity to the skin (Figure 1B). Consequently, the pattern of sensory loss is entirely unique in leprosy, presenting as skin lesions with varying degrees of sensory loss and a ‘stocking-glove’ type of anesthesia in the lepromatous type of leprosy [5], [6], [7], [8].


FIG 1 Microphotographs of peripheral nerve in lepromatous leprosy (A) and cutaneous nerve in skin sections of tuberculoid leprosy (B).

  1. Hematoxylin and eosin section of peripheral nerve fascicles. Clumps of M. leprae were present within this nerve (inset). (HE, scale =50 microns; inset, Fite-Faraco stain, 1000x).
  2. Skin section exhibiting a large granulomatous inflammatory cell collection consisting of small epithelioid cell clusters (arrow) and dense aggregates of lymphocytes infiltrating small dermal nerve bundles (broken arrows) (Hematoxylin & Eosin stain). Scale =100 µm.

M. leprae Entry into Nerves

Though the route of entry of M. leprae into the peripheral nerves is still undetermined, both a direct entry to terminal nerves and a vascular route leading to intraneural infection of M. leprae have been proposed. Autopsy studies have shown that M. leprae bind to the exposed Remak Schwann cells in the dermis, probably through skin abrasions, and ascend directly from cutaneous nerves to the nerve trunks that carry both mixed sensory and motor nerve fibers trunks (Figure 2) [9], [10], [11]. M. leprae infection of endothelial cells is well documented in human leprosy [12]. In experimentally infected armadillos, studies have demonstrated that M. leprae collect in and affect the blood vessels of the epineurial lymphatics and infect the blood vessels of the epineurium. The endothelial cells serve as potential niches for the M. leprae to enter the intraneural compartment [13], [14] (Figure 3). In this view, the perineural inflammation characteristic of leprosy represents the ‘footprints’ of the perineural route of infection.


FIG 2 The initial model of ascending neuritis in leprosy.

With this diagram in 1897, Dehio [9] illustrated his observations from autopsy studies of ascending neuritis involving cutaneous and muscular branches of peripheral nerves in leprosy. Inflammation (hatched areas) was observed to arise from the distal ends of cutaneous nerves in an infected skin lesion and ascend proximally along terminal branches (t) to involve larger mixed nerve bundles. As larger nerve trunks are involved, the inflammation of infected fibers also interferes with the conduction of both sensory and motor impulses in adjacent, non-infected fibers, innervating non-inflamed skin and muscle. This interference results in cutaneous anesthesia in lesions as well as in non-infected skin and in weakness and atrophy of the muscle, even if its nerve is not infected (modified from [9]).


FIG 3 A proposed model of M. leprae infection of nerves by a vascular pathway.

The anatomic and physiological setting in which M. leprae infection occurs within the endoneurium of peripheral nerves is illustrated in this diagram of a small fascicle containing a blood vessel and both myelinated and non-myelinated SC. Axons are individually wrapped in SC, either with or without a myelin sheath (M). External to their cell membrane, SC also elaborate a continuous basal lamina with a biochemically distinctive composition (see text). The small blood vessels that penetrate the perineurium are lined by endothelial cells that are anchored to their own biochemically distinctive basal lamina. No lymphatics are present beneath the perineurial wrapping, but resident macrophages (MΦ) do patrol the interstitial space between nerve fibers and blood vessels.

If M. leprae enter nerves via their blood supply as proposed (see text), then in order to reach the Schwann cell, bacilli must first adhere to and pass through (or between) endothelial cells and cross their basal lamina. Once in the interstitium of the fascicle, bacilli may be bound and ingested by resident macrophages, or they may bind to the basal lamina of a Schwann cell, which then ingests them. (Not illustrated is the possibility that infected circulating mononuclear phagocytes adhere to and migrate between endothelial cells, carrying M. leprae into close proximity to SC.) (Modified from [14]).

Several pathological mechanisms have been proposed for nerve damage in leprosy: the interference of M. leprae cell wall proteins with host cell (macrophage) metabolism, an immune-mediated inflammation triggered by T-cell/SC interactions, and a ‘bystander’ type of nerve injury due to the large influx of cells and edema during the course of immune and inflammatory responses to M. leprae [15], [16]. The resultant immunopathological changes manifest clinically in the form of skin lesions, ocular changes, and peripheral nerve enlargement.

Role of Schwann Cells in Leprosy Neuritis

Binding of M. leprae to Schwann cells

Because of a lack of key functional genes, M. leprae relies predominantly on the host cell for survival, multiplication, and dissemination [17]. The SC serves as an important habitat for M. leprae and as a safe niche in the center of the cellular events that orchestrate the processes of nerve injury. Though M. leprae cannot be cultivated in an artificial media, the availability of SC and SC-axon co-culture models have provided an opportunity for understanding the interaction of the bacilli with SC. Several molecules have been identified that are responsible for M. leprae’s adherence to and ingestion by SC [18], [19]. Specifically, various receptor-mediated mechanisms, Fc receptors, complement receptors [20], the fibronectin binding protein [21], and Toll-like receptor 2 on the surface of SC [22], [23] may play a role in the invasion of human SC by M. leprae.

The organism binds to the G domain of the laminin alpha-2 chain, which is expressed on the surface of the SC-axon unit, through a receptor on M. leprae that is a 21 kDa histone-like protein [24], [25]. This protein, LBP21, coded by the ML1683 gene, is a major exposed surface antigen on M. leprae and serves as an adhesin for its binding with peripheral nerve laminin-2 to initiate the SC invasion. Similarly, the terminal trisaccharide of phenolic glycolipid 1 (PGL-1), which is a surface-exposed M. leprae-specific antigen, has been shown to bind to laminin-2, indicating that PGL-1 also is involved in the entry of M. leprae into SC [26], [27].

Schwann cell interaction and dissemination of M. leprae

There are several theories on the role of infected SC in the dissemination of M. leprae. SC and M. leprae interact to establish a favorable environment for the proliferation of M. leprae. The viability of nude-mouse derived M. leprae in rat SC in vitro is comparable to that of the bacilli surviving within macrophages. The survival of M. leprae within SC in vitro is also conditioned by optimal temperature, as the viability of M. leprae is greater at 33°C than at 37°C [28]. This claim is consistent with histological observations indicating that M. leprae appears to remain dormant and grow within SC in human nerves at superficial, cooler sites.

M. leprae also appears to alter the SC expression of a small number of genes; so far glial fibrillary acidic protein, transforming growth factor β1, NCAM, ICAM, N-cadherin, and L1 have been studied. The functional significance of these alterations with respect to the clinical presentation of nerve injury remains to be determined [28].

SC infected in vitro are able to present M. leprae antigens [29], [30], [31]. The interior milieu of the Schwann cell is also altered by this infection, producing metabolic and functional changes that trigger the immune system in recruiting cytotoxic cells T lymphocytes [32], [33] and macrophages [34], [35].

Experimental studies in-vitro have shown that M. leprae may reprogram adult SC by altering host gene expression, with the bacterially reprogrammed cells resembling progenitor/stem-like cells (pSLC) with mesenchymal traits. The pSLC acquire migratory and immuno-modulatory characteristics; release chemokines, cytokines, and growth/remodeling factors; and disseminate the bacterial infection without being detected by immune cells. These reprogrammed cells possess the ability to attract macrophages, suggesting a potential role of the innate immune response in the initiation of neuropathogenesis during early M. leprae infection [36], [37].

In long-standing lepromatous nerves, the SC exhibit a foamy appearance due to lipid droplets recruited to M. leprae-containing phagosomes, a step mediated through Toll-like receptor-6–dependent signaling [38]. This lipid droplet recruitment may be an effective intracellular strategy by M. leprae to maintain a source for nutrition and persistence within SC.

Axonal degeneration

The precise mechanisms of axonal degeneration may differ at the lepromatous and the tuberculoid portions of the leprosy spectrum (Figure 3). In the development of axonal damage, the potentially different roles of Remak SC and myelinating SC are not clear [4], [39], [40]. One of the primary functions of SC is to synthesize the myelin sheath around axons, and there is evidence that M. leprae–induced demyelination is a result of direct bacterial ligation and activation of the ErbB2 receptor of Neuregulin-1 that regulates normal myelination [41], [42], [43]. Demyelination may be induced by a variety of insults, including high levels of some pro-inflammatory cytokines [44], [45], [46]. The major toxic effector molecule known to kill M. leprae is nitric oxide (NO), produced from L-arginine by activated macrophages expressing the inducible NO synthase (iNOS). Granuloma-associated macrophages have been observed to have iNOS reactivity. Nitrotyrosine, an end product of the metabolism of NO known to cause lipid peroxidation of myelin, has been observed in nerves in BL lesions [47], [48].

The complement system is a key component of the host defense against pathogens. Complement activation results in the cleavage of C3, followed by the cleavage of C5 and the formation of the membrane attack complex (MAC), which causes perforation of eukaryotic cell membranes, resulting in lysis of the target cell [49]. A recent study has shown that in nude-mouse sciatic nerves, intraneural injections of M. leprae sonicate and its components—particularly lipoarabinomannan (LAM)—result in MAC deposition, myelin loss, and axonal damage [50]. Human studies have reported significant serum complement consumption by M. leprae [51]. In addition, MAC deposits have been observed on damaged nerves of lepromatous but not tuberculoid patients [50], [52], suggesting that complement activation—and specifically the MAC—may function as a disease modifier during the early events of leprosy neuritis.


Ultimately, individual axons in nerve bundles undergo segmental demyelination in leprosy [53], [54]. This process may be induced by a variety of insults, including high levels of certain pro-inflammatory cytokines [44], [45], [46] and other mediators of inflammation, along with inflammatory cells forming infiltrating intraneural granulomas [55] (Figure 4).


FIG 4 M. leprae-infected peripheral nerves exhibiting demyelination and fibrosis.

  1. H&E stained sections from a superficial peroneal nerve with many fascicles (arrows) showing massive infiltration of inflammatory cells. Scale = 100 µm
  2. A nerve (arrow) from longstanding lepromatous disease with vacuolated macrophages (arrow heads) and loss of nerve fibers. Scale = 50 µm
  3. Sections of nerve fascicles (arrow) showing focal demyelination and fibrosis (broken arrows). Scale = 100 µm
  4. S100 stained nerve sections (arrows) showing focal degeneration of SC and axons (broken arrow). Scale = 100 µm

Whatever combination of mechanisms of injury develop during infection with M. leprae, the final common pathway of nerve injury is segmental demyelination. Immunohistochemical studies of human nerves have identified TNF and its receptors and TNF-converting enzymes within nerves in patients with Type 1 reactions. Coupled with studies of the induction of TNF by SC in vitro, experimental evidence suggests that SC may be made more sensitive to TNF-mediated injury and focal demyelination [56].

Alteration of Immunohistochemical Markers

The advent of immunohistochemical markers has contributed enormously to the detection and investigation of the injury of small nerve fibers. Skin lesions across the spectrum of leprosy exhibit significant destruction of cutaneous nerves. A study in M. leprae-infected nude mice showed that a decrease of substances P and CGRP in central and peripheral projections of sensory neurons developed at an early stage of infection and was associated with sensory nociception [57]. The levels of TNF in the skin and the nerves of leprosy lesions are similar [58], suggesting that the immunological phenomena studied extensively in leprosy skin lesions also apply to nerves.

Anhydrosis and an impaired sweat response in skin, denervation of the iris, and miotic pupil in the eye are some of the clinical manifestations of autonomic dysfunctions described in lepromatous patients [59], [60]. Though extensive mechanistic studies are needed to investigate the functions of autonomic fibers in leprosy, an absence of protein gene product (PGP 9.5), a pan axonal marker, has been documented in the small nerves of the ciliary body, the scleral nerves, and the posterior ciliary nerves adjacent to the optic nerve in enucleated lepromatous eyes. This phenomenon mirrored the ’glove and stocking‘ type of anesthesia seen in lepromatous patients, in which there is a symmetrical loss of sensation in all four limbs due to an ascending polyneuritis of the extremities [61].

Regeneration of Nerves in Leprosy

Studies have examined the mRNA and protein levels of Ninjurin-1, an adhesion molecule involved in the response to injury and regeneration in peripheral nerves. Both mRNA upregulation and elevated levels of the protein were observed in nerve biopsy specimens from leprosy patients with neuritis [62]. Soft tissue injury, wounds, and ulcers on the lower extremities are frequent complications in lepromatous patients. These findings share a common theme with other small fiber sensory neuropathies, like diabetic neuropathy. Although the regeneration of nerves is possible, regrowth is limited by the milieu of the surrounding extracellular matrix (ECM) as well as vascular insufficiency [63], [64], resulting in poor functional recovery.


Intraneural fibrosis and sclerosis are the major destructive pathological manifestations seen in chronically damaged nerves in leprosy (Figure 4). M. leprae are seen within collagenized lepromatous nerves in advanced stages of the disease. Attempts have been made to understand the role of the extra cellular matrix (ECM) in leprosy nerves, and matrix metalloproteinase (MMP), transforming growth factor-β1 (TGF-β1), and neuro fibroblasts have been implicated. High levels of matrix metalloproteinases (MMP)-2 and MMP-9 were observed in nerves with endoneurial inflammation in leprosy patients, and these MMP are likely produced by SC and intraneural macrophages [65], [66]. It has been proposed that in SC cultures, M. leprae-infected SC undergo phenotypical changes, induce upregulation of transforming growth factor-β1 (TGF-β1), and increase numbers of α-smooth muscle actin (α-SMA)–positive cells. The characteristic change to stress fibers leads them to secrete ECM that may contribute to progressive nerve fiber loss and fibrosis [67].

Neural fibroblasts (Nf) are abundant in the endoneurium and perineurium of peripheral nerves. Primary neural fibroblasts derived from peripheral nerves could serve as a susceptible recipient cell type for M. leprae to escape and survive when these fibroblasts come in contact with infected reprogrammed SC (pSLC) [68]. It is possible that the neural collagenization in advanced leprosy may be of Nf origin [69].

Nerve Injury in the Armadillo Model

The nine-banded armadillo (Dasypus novemcinctus; see Chapter 10.1) is the only other natural host for M. leprae [70], and naïve armadillos can be experimentally infected, as first described by Walsh et al. [71]. The intravenous inoculation of M. leprae in armadillos induces peripheral neuritis and recapitulates many features of human leprosy [13], [72]. Aggregates of M. leprae have been identified within myelinated axons, unmyelinated axons, and SC without producing any intraneural inflammatory cells, thus imitating lepromatous nerves and offering a good experimental model in which to study newer drugs and vaccines. For example, an M. leprae viability study using molecular markers showed that a high load of stainable M. leprae persists within nerves even after the completion of a full year of rifampin. The molecular viability assays (see Chapter 5.3) indicated that the bacilli were not viable, but the dead bacteria and associated antigens remained in the nerves [73]. This experimental finding parallels the persistence and slow clearance of M. leprae in human tissues, even many years after successful anti-mycobacterial therapy [74], [75]. Persisting dead M. leprae provide a continuing source of antigenic stimulation, and may be a major factor in the immuno-pathogenesis of long-term nerve injury in leprosy.

Armadillos respond poorly to thermal, light, or tactile nociceptive stimulants because of their thick carapace, but nerve conduction tests can be done to effectively assess the function of their motor nerves. Several investigators have used immunostaining of cutaneous nerves in 3mm skin punches for PGP9.5 to visualize the intra-epidermal nerve fibers, dermal nerves, and SC in small fiber sensory neuropathies associated with diabetes, HIV, and idiopathic small fiber sensory neuropathies [64], [76], [77], [78]. Similar to humans, studies in naïve animals have shown that the distal peripheral innervation pattern is length dependent, with less nerve fibers in the distal leg in comparison to the abdomen [79], [80] (Figures 5 and 6). Preliminary studies in M. leprae infected armadillos have shown a slow decline of epidermal fibers but a trend towards an increasing proliferation of SC, providing indirect evidence that during early infection SC may proliferate while harboring M. leprae. These studies indicate the feasibility of studying small fibers and early infection in the armadillo using this technique, as well as the possibility of using it as a novel tool to test new drugs and therapeutic interventions.


FIG 5 Epidermal Innervation in Armadillos: Skin sections immunostained with anti-PGP 9.5, a neuronal marker.

Skin sections in armadillos exhibiting length-dependent epidermal innervation, dense in the ear lobes (A) and abdomen (B) of naïve animals (black arrows), as compared to the distal leg (C). (Scale bars, A, B, C = 50 um) (Modified from [72]).


FIG 6 Skin sections of double stained confocal images (A) of dermal axons (anti-PGP 9.5) and (B) SC (anti nerve growth factor receptor, p75).

Distal leg skin section from a naïve animal showing dermal axonal bundles (red arrows) and the SC (green arrow) ensheath and co-localize (yellow arrows) on the dermal axons, exhibiting a pattern similar to human innervation. (Scale bars A, B; C = 20 um) (Modified from [72]).

Summary and Conclusions

In summary, the mechanisms of nerve injury in leprosy can be characterized as follows, although the natural order of the events is not certain:

  • M. leprae prefer the cooler areas of the body for multiplication, and predominantly affect the segments of trunk nerves that are in close contact with the skin.
  • M. leprae appears to enter the endoneurial compartment of nerves via the blood supply and endothelium.
  • Several different molecules on SC bind M. leprae and facilitate its ingestion.
  • M. leprae survive and proliferate within SC.
  • Stimulated by M. leprae, SC produce several proteins that may contribute to demyelination.
  • Infected nerves are physically at the center of chronic inflammation and immunological activity that may persist for many years.
  • Some immune and inflammatory mediators are toxic to nerves and promote demyelination.
  • Segmental demyelination occurs, and regeneration follows in some fascicles; these processes may coexist for years.
  • A large number of dead bacterial cells remain within a nerve even after multi-drug therapy, and may continue to elicit immunological responses and acute and chronic neuritis.

Identifying the sequence in mechanisms of nerve injury in leprosy is challenging because of the bacteria’s dormancy and long incubation period before producing any nerve damage. In addition, the major peripheral nerves affected in man can seldom be biopsied and studied. In spite of these difficulties, extraordinary progress has been made in the last decade, in large part due to new tools resulting from the sequencing of the M. leprae genome and that of the only animal model of leprosy neuropathy, the nine-banded armadillo.


  1. ^ Sabin TD. 1971. Neurologic features of lepromatous leprosy. Am Fam Physician 4:84–94.
  2. ^ Ridley DS. 1971. Pathology and bacteriology of early lesions in leprosy. Int J Lepr Other Mycobact Dis 39:216–224.
  3. ^ Yoshizumi MO, Asbury AK. 1974. Intra-axonal bacilli in lepromatous leprosy. A light and electron microscopic study. Acta Neuropathol 27:1–10.
  4. a, b Job CK. 1970. Mycobacterium leprae in nerve lesions in lepromatous leprosy. An electron microscopic study. Arch Pathol 89:195–207.
  5. ^ Sabin TD. 1969. Temperature-linked sensory loss. A unique pattern in leprosy. Arch Neurol 20:257–262.
  6. ^ Sabin TD, Hackett ER, Brand PW. 1974. Temperatures along the course of certain nerves often affected in lepromatous leprosy. Int J Lepr Other Mycobact Dis 42:38–42.
  7. ^ Brand PW. 1959. Temperature variation and leprosy deformity. Int J Lepr 27:1–7.
  8. ^ Ebenezer GJ, Arumugam S, Job CK. 2002. Dosage and site of entry influence growth and dissemination of Mycobacterium leprae in T900r mice. Int J Lepr Other Mycobact Dis 70:245–249.
  9. a, b, c Dehio K. 1952. On the Lepra Anesthetica and the pathogenetic relation of its disease-appearances. Proceedings of the International Scientific Leprosy Conference in Berlin, Oct., 1897. Translated and reprinted in Leprosy in India 24:78–83.
  10. ^ Gerlach W. 1891. Investigations on anaesthetic skin patches. Virchow’s Archiv 125:126–145.
  11. ^ Dastur DK. 1955. Cutaneous nerves in leprosy; the relationship between histopathology and cutaneous sensibility. Brain 78:615–633.
  12. ^ Fite G. 1941. The vascular lesions of leprosy. Int J Lepr 9:193–202.
  13. a, b Scollard DM, McCormick G, Allen J. 1999. Localization of Mycobacterium leprae to endothelial cells of epineural and perineural blood vessels and lymphatics. Am J Pathol 154:1611–1620.
  14. a, b Scollard DM. 2000. Endothelial cells and the pathogenesis of lepromatous neuritis: insights from the armadillo model. Microbes Infect 2:1835–1843.
  15. ^ Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. 2006. The continuing challenges of leprosy. Clin Microbiol Rev 19:338–381.
  16. ^ Spierings E, De Boer T, Zulianello L, Ottenhoff TH. 2000. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol 78:349–355.
  17. ^ Eiglmeier K, Parkhill J, Honore N, Garnier T, Tekaia F, Telenti A, Klatser P, James KD, Thomson NR, Wheeler PR, Churcher C, Harris D, Mungall K, Barrell BG, Cole ST. 2001. The decaying genome of Mycobacterium leprae. Lepr Rev 72:387–398.
  18. ^ Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL, Yurchenco PD, Campbell KP, Fischetti VA. 1998. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 282(5396):2076–2079.
  19. ^ Teles RM, Krutzik SR, Ochoa MT, Oliveira RB, Sarno EN, Modlin RL. 2010. Interleukin-4 regulates the expression of CD209 and subsequent uptake of Mycobacterium leprae by Schwann cells in human leprosy. Infect Immun 78:4634–4643.
  20. ^ Vedeler CA, Nilsen R, Matre R. 1989. Localization of Fc gamma receptors and complement receptors CR1 on human peripheral nerve fibres by immunoelectron microscopy. J Neuroimmunol 23:29–33.
  21. ^ Schorey JS, Li Q, McCourt DW, Bong-Mastek M, Clark-Curtiss JE, Ratliff TL, Brown EJ. 1995. A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun 63:2652–2657.
  22. ^ Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, Sarno EN, Modlin RL. 2003. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun 71:1427–1433.
  23. ^ Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, Liu PT, Cole ST, Godowski PJ, Maeda Y, Sarno EN, Norgard MV, Brennan PJ, Akira S, Rea TH, Modlin RL. 2003. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9:525–532.
  24. ^ Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL, Yurchenco PD, Campbell KP, Fischetti VA. 1998. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 282:2076–2079.
  25. ^ Shimoji Y, Ng V, Matsumura K, Fischetti VA, Rambukkana A. 1999. A 21-kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proc Natl Acad Sci U S A 96:9857–9862.
  26. ^ Rambukkana A. 2000. How does Mycobacterium leprae target the peripheral nervous system? Trends Microbiol 8:23–28.
  27. ^ Harboe M, Aseffa A, Leekassa R. 2005. Challenges presented by nerve damage in leprosy. Lepr Rev 76:5–13.
  28. a, b Hagge DA, Oby Robinson S, Scollard D, McCormick G, Williams DL. 2002. A new model for studying the effects of Mycobacterium leprae on Schwann cell and neuron interactions. J Infect Dis 186:1283–1296.
  29. ^ Lockwood DN, Colston MJ, Khanolkar-Young SR. 2002. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 66:409–415.
  30. ^ Spierings E, de Boer T, Wieles B, Adams LB, Marani E, Ottenhoff TH. 2001. Mycobacterium leprae-specific, HLA class II-restricted killing of human Schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy. J Immunol 166:5883–5888.
  31. ^ de Melo Marques MA, Mahapatra S, Nandan D, Dick T, Sarno EN, Brennan PJ, Vidal Pessolani MC. 2000. Bacterial and host-derived cationic proteins bind alpha2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells. Microbes Infect 2:1407–1417.
  32. ^ Ford A, Britton, WJ, Armati, PJ. 1993. Schwann cells are able to present exogenous mycobacterial hsp70 to antigen-specific T lymphocytes. J Neuroimmunol 43:151–159.
  33. ^ Steinhoff U, Kaufmann SH. 1988. Specific lysis by CD8+ T cells of Schwann cells expressing Mycobacterium leprae antigens. European Journal of Immunology 18(6):969–972.
  34. ^ Adams LB, Scollard DM, Ray NA, Cooper AM, Frank AA, Orme IM, Krahenbuhl JL. 2002. The study of Mycobacterium leprae infection in interferon-gamma gene—disrupted mice as a model to explore the immunopathologic spectrum of leprosy. J Infect Dis 185 Suppl 1:S1–8.
  35. ^ Adams LB, Pena MT, Sharma R, Hagge DA, Schurr E, Truman RW. 2012. Insights from animal models on the immunogenetics of leprosy: a review. Mem Inst Oswaldo Cruz 107 Suppl 1:197–208.
  36. ^ Masaki T, Qu J, Cholewa-Waclaw J, Burr K, Raaum R, Rambukkana A. 2013. Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection. Cell 152:51–67.
  37. ^ Masaki T, McGlinchey A, Cholewa-Waclaw J, Qu J, Tomlinson SR, Rambukkana A. 2014. Innate immune response precedes Mycobacterium leprae-induced reprogramming of adult Schwann cells. Cell Reprogram 16:9–17.
  38. ^ Mattos KA, Oliveira VG, D’Avila H, Rodrigues LS, Pinheiro RO, Sarno EN, Pessolani MC, Bozza PT. 2011. TLR6-driven lipid droplets in Mycobacterium leprae-infected Schwann cells: immunoinflammatory platforms associated with bacterial persistence. J Immunol 187:2548–2558.
  39. ^ Job CK. 1973. Mechanism of nerve destruction in tuberculoid-borderline leprosy. An electron-microscopic study. J Neurol Sci 20:25–38.
  40. ^ Turk JL, Curtis J, De Blaquiere G. 1993. Immunopathology of nerve involvement in leprosy. Lepr Rev 64:1–6.
  41. ^ Tapinos N, Ohnishi M, Rambukkana A. 2006. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med 12:961–966.
  42. ^ Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. 2004. Axonal neuregulin-1 regulates myelin sheath thickness. Science 304:700–703.
  43. ^ Chen S, Velardez MO, Warot X, Yu ZX, Miller SJ, Cros D, Corfas G. 2006. Neuregulin 1-erbB signaling is necessary for normal myelination and sensory function. J Neurosci 26:3079–3086.
  44. a, b Constantin G, Piccio L, Bussini S, Pizzuti A, Scarpini E, Baron P, Conti G, Pizzul S, Scarlato G. 1999. Induction of adhesion molecules on human schwann cells by proinflammatory cytokines, an immunofluorescence study. J Neurol Sci 170:124–130.
  45. a, b Fujioka T, Kolson DL, Rostami AM. 1999. Chemokines and peripheral nerve demyelination. J Neurovirol 5:27–31.
  46. a, b di Penta A, Moreno B, Reix S, Fernandez-Diez B, Villanueva M, Errea O, Escala N, Vandenbroeck K, Comella JX, Villoslada P. Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One 8:e54722.
  47. ^ Schon T, Hernandez-Pando R, Baquera-Heredia J, Negesse Y, Becerril-Villanueva LE, Eon-Contreras JC, Sundqvist T, Britton S. 2004. Nitrotyrosine localization to dermal nerves in borderline leprosy. Br J Dermatol 150:570–574.
  48. ^ Anggard E. 1994. Nitric oxide: mediator, murderer, and medicine. Lancet 343:1199–1206.
  49. ^ Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M, Vigar MA, van der Wetering S, Morgan BP, Troost D, Baas F. 2007. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 27:7663–7672.
  50. a, b Bahia El Idrissi N, Das PK, Fluiter K, Rosa PS, Vreijling J, Troost D, Morgan BP, Baas F, Ramaglia V. 2015. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathol 129:653–667.
  51. ^ Gomes GI, Nahn EP, Jr., Santos RK, Da Silva WD, Kipnis TL. 2008. The functional state of the complement system in leprosy. Am J Trop Med Hyg 78:605–610.
  52. ^ Parkash O, Kumar V, Mukherjee A, Sengupta U, Malaviya GN, Girdhar BK. 1995. Membrane attack complex in thickened cutaneous sensory nerves of leprosy patients. Acta Leprol 9:195–199.
  53. ^ Swift TR. 1974. Peripheral nerve involvement in leprosy: quantitative histologic aspects. Acta Neuropathol (Berl) 29:1–8.
  54. ^ Jacobs JM, Shetty VP, Antia NH. 1987. Teased fibre studies in leprous neuropathy. J Neurol Sci 79:301–313.
  55. ^ Hagge DA, Saunders BM, Ebenezer GJ, Ray NA, Marks VT, Britton WJ, Krahenbuhl JL, Adams LB. 2009. Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy. Am J Pathol 174:1379–1389.
  56. ^ Andrade PR, Jardim MR, da Silva AC, Manhaes PS, Antunes SL, Vital R, Prata RB, Petito RB, Pinheiro RO, Sarno EN. 2016. Inflammatory Cytokines Are Involved in Focal Demyelination in Leprosy Neuritis. J Neuropathol Exp Neurol 75:272–283.
  57. ^ Karanth SS, Springall DR, Lucas S, Levy D, Ashby P, Levene MM, Polak JM. 1989. Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. J Pathol 157:15–26.
  58. ^ Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, Colston MJ, Lockwood DN. 1995. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99(2):196–202.
  59. ^ Facer P, Mathur R, Pandya SS, Ladiwala U, Singhal BS, Anand P. 1998. Correlation of quantitative tests of nerve and target organ dysfunction with skin immunohistology in leprosy. Brain 121(Pt 12):2239–2247.
  60. ^ Daniel E, Sundar Rao PS, Ffytche TJ, Chacko S, Prasanth HR, Courtright P. 2007. Iris atrophy in patients with newly diagnosed multibacillary leprosy: at diagnosis, during and after completion of multidrug treatment. Br J Ophthalmol 91:1019–1022.
  61. ^ Ebenezer GJ, Daniel E. 2004. Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a “dying back” phenomenon in the posterior ciliary nerves. Br J Ophthalmol 88:178–181.
  62. ^ Cardoso CC, Martinez AN, Guimaraes PE, Mendes CT, Pacheco AG, de Oliveira RB, Teles RM, Illarramendi X, Sampaio EP, Sarno EN, Dias-Neto E, Moraes MO. 2007. Ninjurin 1 asp110ala single nucleotide polymorphism is associated with protection in leprosy nerve damage. J Neuroimmunol 190:131–138.
  63. ^ Miko TL, Le Maitre C, Kinfu Y. 1993. Damage and regeneration of peripheral nerves in advanced treated leprosy. Lancet 342:521–525.
  64. a, b Ebenezer GJ, O’Donnell R, Hauer P, Cimino NP, McArthur JC, Polydefkis M. 2011. Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. Brain 134:1853–1863.
  65. ^ Teles RM, Antunes SL, Jardim MR, Oliveira AL, Nery JA, Sales AM, Sampaio EP, Shubayev V, Sarno EN. 2007. Expression of metalloproteinases (MMP-2, MMP-9, and TACE) and TNF-alpha in the nerves of leprosy patients. J Peripher Nerv Syst 12:195–204.
  66. ^ Oliveira AL, Antunes SL, Teles RM, Costa da Silva AC, Silva TP, Brandao Teles R, Ferreira Medeiros M, Britto C, Jardim MR, Pereira Sampaio E, Nunes Sarno E. 2010. Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy. J Neuropathol Exp Neurol 69:27–39.
  67. ^ Petito RB, Amadeu TP, Pascarelli BM, Jardim MR, Vital RT, Antunes SL, Sarno EN. 2013. Transforming growth factor-beta1 may be a key mediator of the fibrogenic properties of neural cells in leprosy. J Neuropathol Exp Neurol 72:351–366.
  68. ^ Hess S, Rambukkana A. 2015. Bacterial-induced cell reprogramming to stem cell-like cells: new premise in host-pathogen interactions. Curr Opin Microbiol 23:179–188.
  69. ^ Singh N, Birdi TJ, Chandrashekar S, Antia NH. 1998. In vitro studies on extracellular matrix production by M. leprae infected murine neurofibroblasts. Lepr Rev 69:246–256.
  70. ^ Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, Kapopoulou A, Brisse S, Scollard DM, Gillis TP, Cole ST. Probable zoonotic leprosy in the southern United States. N Engl J Med 364:1626–1633.
  71. ^ Walsh GP, Storrs EE, Burchfield HP, Cotrell EH, Vidrine MF, Binford CH. 1975. Leprosy-like disease occurring naturally in armadillos. J Reticuloendothel Soc 18:347–351.
  72. a, b Scollard DM, Lathrop GW, Truman RW. 1996. Infection of distal peripheral nerves by M. leprae in infected armadillos; an experimental model of nerve involvement in leprosy. Int J Lepr Other Mycobact Dis 64:146–151.
  73. ^ Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, Gillis TP. 2008. Enumeration of Mycobacterium leprae using real-time PCR. PLoS Negl Trop Dis 2:e328.
  74. ^ Scollard D, Stryjewska, BM. 2011. Treatment and Prevention of Leprosy. UpToDate.
  75. ^ Daniel E, Ebenezer GJ, Job CK. 1997. Pathology of iris in leprosy. Br J Ophthalmol 81:490–492.
  76. ^ Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW, McArthur JC. 1997. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology 48:708–711.
  77. ^ Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. 2004. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 127:1606–1615.
  78. ^ Goransson LG, Brun JG, Harboe E, Mellgren SI, Omdal R. 2006. Intraepidermal nerve fiber densities in chronic inflammatory autoimmune diseases. Arch Neurol 63:1410–1413.
  79. ^ Scollard DM, Truman RW, Ebenezer GJ. 2015. Mechanisms of nerve injury in leprosy. Clin Dermatol 33:46–54.
  80. ^ Truman RW, Ebenezer GJ, Pena MT, Sharma R, Balamayooran G, Gillingwater TH, Scollard DM, McArthur JC, Rambukkana A. 2014. The armadillo as a model for peripheral neuropathy in leprosy. ILAR J 54:304–314.
multibacillary leprosy
lepromatous leprosy
tuberculoid leprosy
multi-drug therapy
reversal reaction
Type 1